T22 Ethics General

Comprises correspondence with the Riverside Research Ethics Committee relating to the planning, delivery and follow up of the C0168T22 study. Includes news releases relating to the approval of Remicade/Infliximab (cA2), correspondence relating to the final close out of the study, copy of ethics committee final report, final investigators report to Centocor, correspondence relating to protocol renewals/extensions and approval, letters containing details of serious adverse events and SAE reports, ethics approval and submissions and copy of investigators brochure for the information of the ethics committee.

File also contains ethics related reporting from previous cA2 studies.

1997 2003

1 file (3 parts)

This item requires facilitated access. Email library@wellcomecollection.org to request an appointment.